



# Health Economics Forum 2019

An efficient and sustainable healthcare system in Malaysia:  
The challenges, lessons and future

Date 20-21 November 2019 | Time 8am-5pm  
Venue Hilton Hotel, Petaling Jaya

Organiser



**MONASH**  
University

Co-organiser



Pharmaceutical Association of Malaysia

Partners



SOUTHEAST ASIA



INVENTING FOR LIFE



IMS Health & Quintiles are now

The Monash Health Economics Forum 2019 is organised by Monash University Malaysia's School of Pharmacy with the Pharmaceutical Services Division, Ministry of Health Malaysia and the Pharmaceutical Association of Malaysia. On its fifth year, this annual event has established itself as one of the most anticipated events of the local pharmaceutical sector. With the ever increasing health care cost in recent years, fundamental core issues such as efficiency and sustainability of healthcare financing have become the focus of discussion during policy development. This year's Forum is centered on a timely theme, 'An efficient and sustainable healthcare system in Malaysia: The challenges, lessons and future'

This one-and-a half day event will try to address these critical policy issues. Three world-renowned experts from the United Kingdom, Australia and Singapore will share their insights and experience in formulating policies and thereafter the crucial allocation of national healthcare budget – which is not always unlimited – to the healthcare sector.

East meets West: We are bringing to you the challenges, lessons and future of a sustainable and efficient health care

## REGISTRATION

Early bird (before 31 July 2019)  
MOH RM 1000  
Normal RM 1200

To register for the Forum or contact the Secretariat:

+603-79608322 - Ms Janice Law

events@phama.org.my

Registration closes: 31 October 2019

All payment to be made to:  
Payee Name: MPA Sdn Bhd  
Bank: Public Bank  
Account No: 3134715421  
Secretariat Address:  
Block C, C-18-02,  
Dataran 3 Two Square,  
No.2, Jalan 19/1,  
Petaling Jaya, 46300 Selangor.

## KEYNOTE SPEAKERS



### Professor Mark Sculpher University of York, United Kingdom

Professor Mark Sculpher is Professor of Health Economics and is Team Leader of the Program on Economic Evaluation and Health Technology Assessment. He is also Co-Director of the Policy Research Unit in Economic Evaluation of Health and Care Interventions (EEPRU). He has been based at York University since 1997. Between 1988 and 1997, he worked at the Health Economics Research Group at Brunel University; during 1998 he was a visitor in the Department of Clinical Epidemiology and Biostatistics at McMaster University in Canada.

Professor Mark has worked on economic evaluations of a range of technologies including heart disease and various cancers. He has also contributed to methods in the field, in particular relating to decision analytic modelling and handling uncertainty. He has over 250 peer-reviewed publications and is a co-author of two major text books in the area: *Methods for the economic evaluation of health care programs* (OUP, 2015 with Drummond, Claxton, Torrance, and Stoddart) and *Decision modelling for health economic evaluation* (OUP, 2006 with Briggs and Claxton). He was a member of the Second Panel on Cost-Effectiveness in Health and Medicine.

Professor Mark was a member of the National Institute for Health and Care Excellence (NICE) Technology Appraisal Committee between 2004 and 2008, the NICE Public Health Interventions Advisory Committee between 2006 and 2009 and currently sits on the NICE Diagnostics Advisory Committee. He chaired NICE's 2004 Task Group on methods guidance for economic evaluation and was a member of the Methods Working Party for the 2008 update of this guidance. He was a member of the Commissioning Board for the UK NHS Health Technology Assessment Program between 2007 and 2010, and the UK National Institute for Health Research (NIHR)/Medical Research Council (MRC) Methodology Research Panel between 2008 and 2011. He was a member of the NIHR Policy Research Program's Commissioning Panel from 2011-2014. He is currently a member of the MRC-NIHR Methodology Research Advisory Group. Professor Mark is a NIHR Senior Investigator (Emeritus) and is a former President of the International Society of Pharmacoeconomics and Outcomes Research.



### Professor Shu Chuen Li The University of Newcastle, Australia

Professor Shu Chuen Li is Chair Professor, Discipline of Pharmacy & Experimental Pharmacology, School of Biomedical Sciences, University of Newcastle. Prior to this, Professor Li has worked as an academic at the National University of Singapore (NUS) and as Acting Director & Deputy Director, Pharmaceutical Evaluation Section (PES) of Pharmaceutical Benefits Branch, Australian Commonwealth Department of Health & Ageing. During his period in Singapore, Professor Li also served as the Visiting Specialist /Consultant to the Health Sciences Authority (HSA), and has been instrumental in developing the Pharmacoeconomics and Drug Utilisation Unit at the Centre for Drug Administration. In his capacity as Acting Director & Deputy Director of PES in Australia, Professor Li was among the few pioneers that put the principles of pharmacoeconomic evaluation into practice for regulatory affairs, and has been involved in implementing the first version of the Australian Pharmacoeconomics Guidelines and developing the second version of the same Guidelines. Professor Li is the immediate past president of Asian Association of Pharmacy Schools (AASP), and was a Director of ISPOR from 2006-2008, and a founding member of the ISPOR Asia Consortium.

Additionally, Professor Li holds many other consultative positions in Australia and in various Asian countries for the past years. The main ones include: Visiting Professorships at Department of Pharmacy, NUS; School of Pharmacy, Fudan University, China; Faculty of Pharmaceutical Science, Prince of Songkla University, Thailand; Centre for Health Services Research, Yong Loo Lin School of Medicine, NUS; Department of Pharmacy, National University of Malaysia (UKM); School of Pharmacy, Taylor University Malaysia; as well as Visiting Specialist/Consultant, Centre for Drug Administration, HSA, Singapore. Professor Li has many years of experience working in many areas of pharmacy, including both hospital and community. He is very active in disseminating his research results and has published more than 400 peer review manuscripts and abstracts. He is a sought after speaker in many international conferences.



### Professor Phua Kai Hong National University of Singapore

Professor Phua Kai Hong lectures in Health Economics at the Singapore Management University and holds adjunct appointments at the Lee Kuan Yew School of Public Policy and the Saw Swee Hock School of Public Health, National University of Singapore. He is also Visiting Professor in Health Policy, Graduate School of Public Policy, Nazarbayev University. He was previously a tenured Associate Professor and Head, Health Care Division and Head, Health Services Research Unit, Department of Community, Occupational & Family Medicine, Faculty of Medicine, National University of Singapore and Adjunct Senior Fellow at the Institute of Policy Studies, Singapore. He graduated with honours cum laude from Harvard University and received graduate degrees from Harvard School of Public Health (Master's in Health Services Administration & Population Sciences) and London School of Economics & Political Science (PhD in Social Administration specialising in Health Economics).

As the Principal Investigator, he led the Rockefeller-funded project on Asian Trends Monitoring awarded to the Lee Kuan Yew School of Public Policy and the Centre for Strategic Futures (2010-2015). He led the Asian component of an Asia-Europe Foundation (ASEF) comparative research project on health and migration (2016). He served on the WHO Expert Committee on The Economics of Healthy Ageing, 2017-2019, and was an invited speaker on Primary Health Care for Migrants at the 2018 WHO Conference on Primary Health Care held in Astana.

Professor Phua received The Outstanding Young Person (TOYP) award in 1992 for his contributions to health policy and community service in Singapore. He was a past Vice-Chairman of the Singapore Red Cross, Board of Management of the Home Nursing Foundation and founder Council Member and Chairman, Resource Committee of the Gerontological Society. He was Chairman of the Task Force on Social Services 2015, to develop a strategic plan for the National Council of Social Service. He was appointed on many national advisory committees, including the Government Parliamentary Committee Resource Panel on Health (1988-1996, 2007-2016). He has consulted for numerous governments and international agencies throughout the Asia-Pacific region, including the Asia-Pacific Academic Consortium for Public Health, International Red Cross, Asian Development Bank, United Nations Economic and Social Commission for the Asia-Pacific, World Bank and World Health Organisation.

## KEYNOTE SPEAKERS



### Professor Adrian Towse Office of Health Economics, United Kingdom

Adrian Towse, MA, MPhil, is the Director of the Office of Health Economics (OHE). OHE is a charitable research organisation (registration number 1170829) which also has a consulting arm (OHE Consulting Ltd). OHE works in the related fields of the economics of HTA, the economics of health care systems and the economics of the life sciences industry. Adrian Towse is a Visiting Professor at the London School of Economics and a Visiting Senior Researcher at the Health Economics Research Centre, Nuffield Department of Population Health at the University of Oxford. Adrian also has been a visiting Professor at the University of York, and for ten years he served as a Non-Executive Director of the Oxford University Hospitals NHS Trust, one of the UK's largest teaching and research hospitals. He chaired the Governance Committee overseeing arrangements for delivering clinical quality.

Adrian has published on 'risk- sharing' arrangements between payers and manufacturers; value -based pricing; HTA development in emerging markets; the economics of stratified (personalized) medicine for payers and the industry; differential pricing, the use of ICERs to arrive at optimal pricing across countries; economic issues that affect both R&D for and access to treatments for diseases prevalent in the developing world; and the economics of medical negligence. Adrian was educated at Keble College, University of Oxford, Nuffield College, University of Oxford, and the Oxford Centre for Management Studies (now the Said Business School). He is also a Member of the Chartered Institute of Management Accountants. Adrian served on the ISPOR Board of Directors 1999-2001 and subsequently on the ViH Management Board. He has played an active role in the scientific life of ISPOR, presenting at ISPOR Plenary sessions in the US and Europe as well as many Issues Panels and Workshops. He was a member of the Task Force on Prospective Observational Studies and the co-Chair of the Task Force on Performance Based Risk Sharing Agreements (PBRsAs). He has given pre-conference training sessions on PBRsAs with colleagues from the University Of Washington School Of Pharmacy for the last nine years. Adrian served as President of ISPOR in the year 2014-2015.

Monash University Malaysia is a joint venture

Jeffrey Cheah  
Foundation



MONASH  
University